Suchergebnisse - "McDonald, Craig M"

PubPharm (280)

11

Correction to : Safety and effectiveness of ataluren in patients with nonsense mutation DMD in the STRIDE Registry compared with the CINRG Duchenne Natural History Study (2015-2022): 2022 interim analysis

enthalten in: Journal of neurology | 2023

von Mercuri, E. | Osorio, A. | Muntoni, F. | +14

ErratumFor: J Neurol. 2023 Aug;270(8):3896-3913. - PMID 37115359

12

Safety and effectiveness of ataluren in patients with nonsense mutation DMD in the STRIDE Registry compared with the CINRG Duchenne Natural History Study (2015-2022) : 2022 interim analysis

enthalten in: Journal of neurology | 2023

von Mercuri, E. | Osorio, A. | Muntoni, F. | +14

ErratumIn: J Neurol. 2023 Sep;270(9):4583. - PMID 37460854

13

Correction to: Safety and effectiveness of ataluren in patients with nonsense mutation DMD in the STRIDE Registry compared with the CINRG Duchenne Natural History Study (2015–2022): 2022 interim analysis

enthalten in: Journal of neurology | 2023

von Mercuri, E. | Osorio, A. | Muntoni, F. | +13

14

Correction to: Safety and effectiveness of ataluren in patients with nonsense mutation DMD in the STRIDE Registry compared with the CINRG Duchenne Natural History Study (2015–2022): 2022 interim analysis

enthalten in: Journal of neurology | 2023

von Mercuri, E. | Osorio, A. | Muntoni, F. | +13

15

Safety and effectiveness of ataluren in patients with nonsense mutation DMD in the STRIDE Registry compared with the CINRG Duchenne Natural History Study (2015–2022): 2022 interim analysis

enthalten in: Journal of neurology | 2023

von Mercuri, E. | Osorio, A. | Muntoni, F. | +13

16

Safety and effectiveness of ataluren in patients with nonsense mutation DMD in the STRIDE Registry compared with the CINRG Duchenne Natural History Study (2015–2022): 2022 interim analysis

enthalten in: Journal of neurology | 2023

von Mercuri, E. | Osorio, A. | Muntoni, F. | +13

17

Safety and effectiveness of ataluren in patients with nonsense mutation DMD in the STRIDE Registry compared with the CINRG Duchenne Natural History Study (2015–2022): 2022 interim analysis

enthalten in: Journal of neurology | 2023

von Mercuri, E. | Osorio, A. | Muntoni, F. | +13

18

Disease progression rates in ambulatory Duchenne muscular dystrophy by steroid type, patient age and functional status

enthalten in: Journal of comparative effectiveness research | 2023

von McDonald, C. | Marden, J. | Shieh, P. | +8

19

Efficacy and Safety of Viltolarsen in Boys With Duchenne Muscular Dystrophy : Results From the Phase 2, Open-Label, 4-Year Extension Study

enthalten in: Journal of neuromuscular diseases | 2023

von Clemens, P. | Rao, V. | Connolly, A. | +8

20

Assessing the value of delandistrogene moxeparvovec (SRP-9001) gene therapy in patients with Duchenne muscular dystrophy in the United States

enthalten in: Journal of market access & health policy | 2023

von Klimchak, A. | Sedita, L. | Rodino-Klapac, L. | +4